In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...

"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and ...

Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a ...

Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with ...

Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third quarter compared to the second. The uptick could also reflect normal ...

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease.

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the returning administration’s effect on issues like Medicaid spending ...

PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...